Background: Interleukin 17 (IL-17) is produced by highly inflammatory Th17 cells and has been implicated in pathophysiology of depression. IL-17 putatively disrupts the blood brain barrier and affects dopamine synthesis whereas dopamine has been shown to decrease Th17 cell-mediated immune response. Nevertheless, whether IL-17 can predict differential treatment outcome with antidepressants modulating dopaminergic transmission is unknown. Methods: IL-17 and other T cell and non-T cell markers (Th1, Th2 and non-T cell markers) were measured with the Bioplex Pro TM human cytokine 27-plex kit in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants who provided baseline plasma and were treated with either bupropion plus escitalopram (bupropion-SSRI), escitalopram plus placebo (SSRI monotherapy), or venlafaxine plus mirtazapine (n = 166). Differential changes in symptom severity and side-effects based on levels of IL-17 and other T and non-T cell markers were tested using a treatment-arm-by-biomarker interaction in separate repeated measures mixed model analyses. Subsequent analyses stratified by treatment arm were conducted for those markers with a significant interaction. Results: There was a significant treatment-arm-by-IL-17 interaction for depression severity (p = 0.037) but not for side-effects (p = 0.28). Higher baseline IL-17 level was associated with greater reduction in depression severity (effect size = 0.78, p = 0.008) in the bupropion-SSRI but not the other two treatment arms. Other T and non-T cell markers were not associated with differential treatment outcomes. Conclusion: Higher baseline levels of IL-17 are selectively associated with greater symptomatic reduction in depressed patients treated with bupropion-SSRI combination.
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Introduction
Inflammation is implicated in both the pathophysiology of depression as well as the lack of response to currently available antidepressant medications (Dantzer et al., 2008; Miller and Raison, 2015) . The role of Interleukin 17 [IL-17, initially identified in 1995 (Yao et al., 1995 ] and the IL-17 producing T-helper (Th) lymphocytes [Th17, identified as distinct from the common Th1 and Th2 sub-types in 2005 (Park et al., 2005 Harrington et al., 2005) ] in systemic inflammation have gained recent attention (Jin and Dong, 2013; Dong, 2008) . Their role in pathophysiology of depression was suggested recently by Beurel et al. in animal experiments where 1) levels of Th17 cells increased in brain after learned helplessness and chronic resistant stress paradigms; 2) infusion of Th17 cells resulted in depression-like behaviors; 3) infusion of anti-IL-17 antibody or inhibition of retinoid-related orphan receptor-cT (RORcT, a transcription factor essential for differentiation of naïve CD4+ T cells to Th17 cells) with SR1001 mitigated the effects of Th17 cell infusion; and 4) RORcT knockout mice exhibited marked resistance to the learned helplessness paradigm (Beurel et al., 2013) . In human studies, Chen et al. found that depressed patients (n = 40), as compared to control subjects (n = 30), had significantly higher Th17 cells and lower regulatory T cells in peripheral circulation, along with higher levels of RORcT mRNA in peripheral blood lymphocytes (Chen et al., 2011) . Elevated levels of IL-17 have also been associated with anxiety in
